You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
高瓴持股36%,嘉和生物將再掀港股IPO熱潮

港股市場鍾愛的“-B”生物醫藥股又要上新啦!

彭博報道,嘉和生物計劃9月下旬開始招股,10月初上市。市場已經摩拳擦掌,在新股扎堆的旺季,部分投資者甚至預留部分資金備戰嘉和生物,到底是什麼讓投資者如此垂青?

嘉和生物是一家尚未商業化的生物製藥公司,專注於腫瘤和自身免疫性藥物的研發。

目前產品管線非常豐富,涵蓋15款靶向候選藥物,其中包括全球前三大腫瘤靶標和十款最暢銷藥物中的五款,簡而言之,這些產品的商業潛力都非常巨大。

公司預計最早在今年下半年提交新藥申請(NDA),第一款是用於治療乳腺癌的GB221是曲妥珠單抗的仿製單抗,預計2020年將繼續成爲全球第二大腫瘤靶標,全球銷售額約129億美元。第二款是生物藥的大熱門PD-1,對於這個擁擠的賽道,嘉和生物另闢蹊徑,選擇外周T細胞淋巴瘤爲爲切入點,有望成爲中國首款治療該疾病的PD-1單抗,目前上市申請已經獲得受理。

生物醫藥股行情火爆

遠的不說,今年上市的未盈利生物醫藥股有6只,無一破發,以上市首日的收盤漲幅來看,表現非常亮眼。

諾誠健華-B漲9.6%

康方生物-B漲50%

沛嘉醫療-B漲68%

開拓藥業-B漲6.7%

歐康維視生物-B漲152%

永泰生物-B漲41%

中1手沛嘉或歐康,首日賣出都能獲利1萬港元以上。

頂級機構加持

生物醫藥公司的專業性較強,一般來說普通投資者難以清楚掌握,如何判斷是否值得打新?最簡單的方法就是看投資者結構,一般出現頂尖的IPO前股東或基石,很多投資者就會選擇all in。

嘉和生物的第一大股東是大名鼎鼎的高瓴資本,持股比例高達36%,A股上市的製藥企業康恩貝是第二大股東,持股16%,此外,淡馬錫、海通證券旗下投資資金、AH上市的臨牀CRO龍頭泰格醫藥均有入股。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account